[Home] [Headlines] [Latest Articles] [Latest Comments] [Post] [Sign-in] [Mail] [Setup] [Help]
Status: Not Logged In; Sign In
|
Health See other Health Articles Title: Micromet's Programmed (cancer) Cell Death In the coming days and weeks, we expect you’ll start hearing the news about this revolutionary CANCER treatment. Media reports about a remarkable new cancer-fighting drug (we call it PCD for Programmed Cell Destruction) will build in frequency, until it appears on “60 Minutes.” But you’ll already know about it well in advance. Yet unlike the “single-cancer” medications above, the unique technology behind PCD could be harnessed to help treat virtually every type of cancer… and with unprecedented effectiveness. We’re constantly scanning the globe for little-known companies that are poised to break out. And we’ll travel from San Francisco to Singapore, from Rio to Reykjavik to find them. We first spotted the company behind PCD in late 2008, when one of our own researchers – with a personal interest in cancer treatment – mentioned some amazing work being done outside of Washington. Now, the company that makes PCD is in the sweet spot, ready to break out like a champagne cork. We believe that time is now. Already the company is in discussions on collaborative partnerships and licensing agreements with no less than five major pharmaceutical companies. The scientific and medical community is electrified. And it’s no wonder. This miraculous breakthrough… * Step One#: PCD makes the body’s own T-cells (the most powerful, natural cancer killers), find the cancer cells. And then it actually makes these T-cells LINK ON to them. This has never been done before. You see, thanks to PCD, these T-cells are made to “lock on” in a new way… a way that the cancer cell simply doesn’t recognize – and thus can’t defend against. * Step Two#: Cancer-killing agents are released that literally punch holes right into the tumor cell. That’s followed by an assault of natural T-cell proteins that create the “programmed cell death.” At this stage, tumors are destroyed. Without chemo, radiation or side effects. Stock PLTG is an Exxon in the making! When things go on sale savvy investors step in and buy, it's that simple. Right now oil is on sale. Make sure you add PLTG to your watch list. It's hard to find a small cap... + Full Story Three Success Tips on Trading Options By Lynn Carpenter Let’s talk about cocktails today. We’ll be careful to use both halves of the word. George Carlin died; boy I’ll miss his humor. I’m not much of a swearer... + Full Story And yet, the next stage is even more amazing… * Step Three#: As soon as the destruction of one cancer cell is underway, the Warrior cell breaks away and moves to the nearest adjacent cancer cell, where it strikes again! Throughout the killing process, the body’s own T-cells start to proliferate. This leads to an increased number of cancer-killing T-cells at the site of attack. The tumor area soon has an ever-growing army of cancer-killing “Warrior Cells.” This is like beating cancer at its own game. PCD currently fights leukemia and lymphomas. But that’s just the beginning. Its unprecedented “seek and destroy” mechanism could soon radically improve a wide variety of cancer treatments… including Rituxan, Herceptin and many others. It could even treat autoimmune and inflammatory diseases, such as arthritis, asthma, even heart disease and multiple sclerosis. Considering the potential impact of PCD we expect it could soon hold a market share worth $7.5 billion. We’ve just completed our full research report on the tiny Maryland company that created “PCD.” It’s called: The "Smart Drug" Breakthrough That Can Turn $10,000 into $200,000.
Post Comment Private Reply Ignore Thread Top • Page Up • Full Thread • Page Down • Bottom/Latest
#1. To: All (#0)
Micromet, Inc. (Micromet) is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based therapies for the treatment of cancer. The Company’s product development pipeline includes antibodies generated with its BiTE antibody platform, as well as conventional monoclonal antibodies. As of December 31, 2009, five of its antibodies are in clinical trials, while the remainder of its product pipeline is in preclinical development. Micromet’s lead product candidate is the BiTE antibody blinatumomab, also known as MT103. Blinatumomab targets the human protein molecule CD19, which is expressed on the surface of tumor cells of certain cancers. Micromet is also evaluating blinatumomab in an ongoing phase I clinical trial for the treatment of patients with non-Hodgkin’s lymphoma (NHL). Its second clinical-stage BiTE antibody MT110, is in a phase I clinical trial for the treatment of patients with solid tumors. Stock is a favorite among some touters but at the current 5.70 doesn't seem to be moving much (what with the 460-million cap.
this is timely as I have a young friend who's got pancreatic cancer. I passed it on to her sister. thanks for the post.
|
||
|
[Home]
[Headlines]
[Latest Articles]
[Latest Comments]
[Post]
[Sign-in]
[Mail]
[Setup]
[Help]
|
||